Loading
Total declarations
Company
▲ Purchases (5 ops.)
▼ Sales (0 ops.)
Latest filing published 09 Apr 2026 for Clover Biopharmaceuticals, Ltd. - B.
Insider track record
Disclosed buys
5
Disclosed sells
0
Signal history
No signal scores available.
Closed purchases
Market purchases
1
Not enough history yet: 0 closed purchases, at least 2 are needed.
Purchases by company
Since each purchase
- -35.4%Entry HK$2.85 · Close 05 Oct 2026 HK$1.84
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Liao Xiang: trading record in brief
Liao Xiang (chief executive) discloses dealings in Clover Biopharmaceuticals, Ltd. - B to HKEX. Over a trading history stretching from 5 November 2021 to 2 April 2026, the count stands at 13 filings.
On the market, this insider has only ever bought: 5 purchases. No amount is published for 5 filings, which the totals therefore leave out. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. In 2026 alone, the filings show 1 purchase and no sales.
On 9 April 2026 came the latest disclosure, a transaction in Clover Biopharmaceuticals, Ltd. - B. The most recent open-market purchase was published on 1 April 2026, 207 days ago. Typically, a trade is published a median of 5 days after it takes place. This delay matters because a trade only becomes useful information once it is public. This summary is built from HKEX disclosures alone and does not predict where the share price will go.
Companies and markets linked to Liao Xiang
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations2 total
49,000 sharesShareXHKGHKEX:DA20260409E00117
340,000 sharesShareXHKGHKEX:DA20260401E00058
Canonical exit: 25 Jun 2026 (T+90)
2 of 2 declarations
